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Abstract Treatment of herpes infections with nucleoside
analogues requires as an initial step the activation of the
compounds by thymidine kinase. As an aid to developing more
effective chemotherapy, both for treatment of recurrent herpes
infection and in gene therapy systems where thymidine kinase is
expressed, two high-resolution X-ray structures of thymidine
kinase have been compared: one with the relatively poor
substrate aciclovir (Zovirax), the other with a synthetic inhibitor
having an N2-substituted guanine. Both compounds have similar
binding modes in spite of their size difference and apparently
distinct ligand properties.
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1. Introduction
Herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) can
give rise to painful mouth, corneal or genital ulcers. HSV-1
thymidine kinase (ATP:thymidine 5-phosphotransferase; EC
2.7.1.21) (TK) is the centre of activation of antiviral drugs
such as aciclovir (Zovirax) [1,2]. Such nucleoside analogues
block the viral replication process, ¢rstly being phosphory-
lated by virally encoded TK or TK-related enzymes, and sub-
sequently terminating DNA elongation at the viral DNA pol-
ymerase. Selectivity is ensured through the inability of the
host-cell TK to phosphorylate these drugs to any appreciable
extent. These compounds have been employed in viral studies
of TK mutations [3], and have also been used in gene therapy
for cancer [4,5] to achieve selective toxicity after introduction
of the viral TK gene into tumour cells. TK itself is not a direct
target for antiviral therapy, because the enzyme is not re-
quired for virus replication in proliferating cells. However,
viral TK activity may be required for reactivation of virus
from latency in nerve cells [6]. TK inhibitors have potential
use in treatment of recurrent herpes infections [7].
Whilst it has a good reputation as an antiherpetic drug,
aciclovir has rather poor e⁄cacy, being a weak substrate for
TK, in spite of the strong chain-terminating e¡ect of its tri-
phosphate. As part of the search for novel TK inhibitors,
which could be useful chemotherapeutic agents to prevent
recurrent herpes infections, a group of compounds based on
N-phenyl derivatives of guanine has been developed [8]. Some
of these display good competitive inhibition, especially one
acyclic nucleoside analogue, 9-(4-hydroxybutyl)-N2-phenyl-
guanine (HBPG), which does not act as a substrate. HBPG
has been found to reduce the frequency of recurrent HSV-1
ocular disease in two animal models [9,10]. Two molecular
modelling studies on the binding of N2-phenylguanines to
TK gave di¡ering results, one [11] predicting such compounds
to bind in a manner distinct from that found [12,13] for gan-
ciclovir, the other [14] predicting, for HBPG, a similar binding
mode.
X-ray studies on a range of HSV-1 TK/ligand complexes to
medium and high (2.14 Aî ) resolutions have been reported
[12,13,15,16]. This X-ray study was undertaken under cryo-
cooled conditions at higher resolution (1.9 Aî ), ¢rstly to deter-
mine details of aciclovir binding not clearly characterised to
date, and secondly to see if the high a⁄nity and lack of sub-
strate activity of HBPG could be understood in structural
terms.
2. Materials and methods
2.1. Crystallisation and data collection of TK/aciclovir and TK/HBPG
binary complexes
Expression and puri¢cation of residues 11^376 of the complete 376
amino acid thymidine kinase peptide has been described previously
[12,17,18]. Crystals of the TK/deoxythymidine (dT) complex were
formed by vapour di¡usion in which 8 Wl of protein solution consist-
ing of 1.0 mg/ml HSV-1 TK, 40 mM Tris-HCl pH 7.5, 3 mM DTT
and 0.2 mM deoxythymidine were mixed with 4 Wl of precipitating
solution (30% saturated ammonium sulphate, 200 mM Tris-HCl pH
6.75, 3 mM DTT and 0.2 mM deoxythymidine), the mixture being
equilibrated against the precipitating solution at 25‡C. The crystals
belong to orthorhombic space group C2221. Exchange of bound de-
oxythymidine for aciclovir or HBPG [8] was done by soaking crystals
¢ve times in 3 ml of solution containing a stoichiometric amount of
compound, 33% saturated ammonium sulphate and 100 mM Tris-HCl
pH 6.75. Crystals were £ash-frozen by transfer to a cryoprotecting
solution (33% saturated ammonium sulphate, 100 mM Tris-HCl pH
6.75, 25% glycerol, and compound) before being mounted in a cryo-
stream for in-house X-ray inspection. Cryocooled crystals showing
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di¡raction to at least 1.9 Aî resolution were taken to the 6 GeV
synchrotron source at ESRF Grenoble using an in-house system
[19] consisting of a portable cold nitrogen stream which allows crys-
tals to be transferred from goniometer to a storage vessel and back to
a goniometer. Full three-dimensional data were collected at ESRF
(station BM14) on a Mar345 imaging plate. Data from 90‡ oscillation
range (0.8‡ per plate) were processed with DENZO/SCALEPACK
[20], and TRUNCATE from the CCP4 suite [21]. Statistics of data
processing are shown in Table 1A.
2.2. Re¢nement of molecular models of complexes
Co-ordinates of the latest best TK/dT model [13] (with ligand and
active-site water molecules excluded) were used as a starting point for
re¢nement of atomic positions and temperature factors against data
from the TK/aciclovir and TK/HBPG complexes. Re¢nement and
di¡erence Fourier electron density map calculation were done using
X-PLOR [22,23], as described previously [13]. Modelling was done on
an Evans and Sutherland Freedom workstation using the program O
[24]. Re¢nement statistics are given in Table 1B. Co-ordinates will be
deposited with the Protein Data Bank at Brookhaven.
3. Results
The structure of the TK/aciclovir complex, previously
solved to 2.37 Aî resolution, has now been extended to 1.9 Aî
through use of a high-energy synchrotron source. The new
complex of TK/HBPG was similarly examined to 1.9 Aî
resolution. Both sets of data were collected from cryocooled
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Fig. 1. Stereo view of the binding of (A) aciclovir and (B) HBPG to TK (molecule 1) superimposed on a di¡erence Fourier map contoured at
3Uc density and showing intermolecular hydrogen bonds. Owing to ambiguity in the density for the hydroxyethoxymethyl group of aciclovir
(see text), two possible locations for the group are indicated in A.
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crystals, a novel method [19] having been used for transpor-
tation of such crystals following initial in-house evaluation.
The overall fold of the enzyme, and binding of several nucleo-
side analogues have been described previously [13]. There are
two molecules in the asymmetric unit.
3.1. TK/aciclovir complex
In the earlier aciclovir structure determination [13] it was
possible to make a structural interpretation of the di¡erence
density for molecule 1 only. The quality of di¡erence density
for molecule 2 is improved with the new high-resolution data,
and is now interpretable. The binding mode observed for
molecules 1 and 2 broadly con¢rms the location of the gua-
nine moiety previously reported for molecule 1[13]. In respect
of the hydroxyethoxymethyl chain, density for molecule 2
appears to extend so that the chain can be modelled with a
hydroxyl location mimicking the location of the 5P-hydroxyl
group of the substrate dT. Although this is in the region of
the side chain of Glu-83 and nearby waters, all are too distant
to be modelled with hydrogen bonds. The unbranched chain
cannot also mimic the 3P-hydroxyl location, near to the Tyr-
101 side chain. By contrast, for molecule 1, while there is also,
albeit detached, density close to the 5P-hydroxyl position (rep-
resenting structure which can interact via hydrogen bonds
with Lys-62, Glu-83, Asp-162 and Arg-163), di¡erence density
continuous at the 2.5Uc level suggests an equally likely in-
terpretation in terms of a 3P-hydroxyl mimic, which would
make a hydrogen bond to the hydroxyl group of Tyr-101
(Fig. 1A). This suggests the viability of alternative conforma-
tions for the molecule 1 hydroxyethoxymethyl group, both
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Table 1
X-ray statistics for thymidine kinase/ligand complexes
A: X-ray re£ection-data statistics
Ligand C2221 unit cell (Aî ) Resolution (Aî ) Rsym Unique data Completeness
a b c All data Outer shell
Aciclovir 114.1 117.8 108.8 1.82 0.045 63 458 97% 57%
HBPG 113.4 118.0 109.0 1.87 0.044 55 222 92% 41%
B: Re¢nement of molecular models
Ligand No. of data Resolution
(Aî )
Completeness
(cmin)
R value
(Rfree)
No. of waters RMS bond
(Aî )
Mean B
(Aî 2)
Aciclovir 47 727 1.90 83% (3.0) 0.241 (0.317) 292 0.012 22.5
HBPG 49 954 1.90 89% (3.0) 0.225 (0.289) 293 0.012 18.8
A: Statistics from Denzo/Scalepack processing [20]. Rsym =gMIi3GIfM/gIi ; where Ii is the measured intensity of an individual re£ection, and GIf the
mean of repeated measurements. Completeness for outer shell gives percentage of data in resolution range 2.00^1.93 Aî with Is 2.0Uc(I).
B: The number of X-ray data are those extending to the resolution stated and for which cscmin. R value is a measure of the agreement between
calculated and observed X-ray data: R =gMMFobsM3MFcalcMM/gMFobsM where Fobs and Fcalc are the observed and calculated structure factors respec-
tively. Rfree is similarly de¢ned for a test set (10%) of the re£ections excluded from driving re¢nement. RMS bond (X-PLOR software) is a measure
of the discrepancy between re¢ned and standard bond lenghts. Mean B is the average temperature factor of main chain atoms after two pairs of
positional and temperature-factor re¢nement rounds. The mean B for aciclovir and HBPK non-hydrogen atoms are 27.4 and 15.1 Aî 2 respectively.
Fig. 2. Stereo view of the molecule 1 active site of the TK/HBPG complex (grey) overlaid on the active site of the TK/aciclovir complex (white)
after alignment of enzyme molecules. (Water molecules in the HBPG complex are labelled ‘w’.)
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having comparable binding enthalpy and both present in the
crystal. For the guanine moiety, there is a water molecule
hydrogen-bonded to both the 2-NH2 group and the side chain
carbonyl of Gln-125. Gln-125 forms the classical pair of hy-
drogen bonds with ligand groups 1NH and O6. The positions
of the guanine group and Arg-176 side chain indicate an ab-
sence of strong hydrogen bonding between aciclovir and Arg-
176 (the same result was obtained for ganciclovir [13]),
although, in molecule 1, the O-NH2 group and ligand O6
are close (3.3 Aî ); for molecule 2 (not shown), di¡erence den-
sity suggests indirect hydrogen bonding for these atoms, via a
water molecule.
3.2. TK/HBPG complex
The di¡erence density for this compound is unambiguous
for both molecules of the asymmetric unit (Fig. 1B), and the
binding mode is essentially the same for both. The un-
branched hydroxybutyl chain, an isostere of the correspond-
ing group in aciclovir, interacts with the carboxylate of Glu-83
and, via a water molecule, with the side chains of Lys-62 and
Arg-163. This mimics the location and interactions of the 5P-
hydroxyl of substrate dT [13]. The binding location of the
guanine portion of this ligand is essentially the same as de-
scribed above for aciclovir with the slight di¡erence that the
larger HBPG is constrained into closer and more numerous
contacts with surrounding active site atoms; for example, the
N7 and O6 atoms of guanine are clearly in hydrogen bond
range of the guanidinium of Arg-176. Gln-125 side chain in-
teracts as expected with N1 and O6 of guanine. The N2-phe-
nyl group is in van der Waals contact with non-polar atoms of
several residues (Tyr-132, Arg-163 and Ala-168 have atoms
within 3.5 Aî , and Trp-88, Met-128 and Tyr-172 also have
atoms nearby); the 2-NH group interacts via a water molecule
with polar groups of Gln-125 and Ala-168. The torsion angle
pairs for the N2-phenyl moieties of molecules 1 and 2 are
(180‡,30‡) and (3170‡,10‡) respectively.
4. Discussion
We have now clari¢ed that aciclovir binding (for both mol-
ecules in the asymmetric unit) is similar to that reported for
ganciclovir and penciclovir [13]. Like ganciclovir [13], aciclovir
does not completely ¢ll the active site of TK. Unlike dT and
uracil analogues [13,25], the base moiety does not readily form
a double hydrogen bond with the side chain of Arg-176. How-
ever, despite repeated attempts to obtain unambiguous infor-
mation, a single mode of binding for aciclovir’s hydroxyethox-
ymethyl group is still not clearly established. It is therefore
likely that the di¡erence density maps highlight a real ambi-
guity: the presence of two binding modes for the group of
comparable binding energy, one locating the hydroxyl in the
5P position of substrate dT, the other in the 3P position. Pre-
sumably the presence of only one hydroxyl group with which
to mimic the 3P- or 5P-hydroxyl groups of dT contributes to
aciclovir’s weak binding.
By contrast HBPG binds strongly to TK [8]. Whilst, like
aciclovir, HBPG has an unbranched acyclic hydroxyl-bearing
group, it nevertheless shows an unambiguous binding mode
for the group. The N2-phenyl group is probably a decisive
factor in the stronger binding. The presence of the group
appears to constrain the guanine into closer proximity with
Arg-176, the ligand forming hydrogen bonds with this residue.
The N2-phenyl group makes a good van der Waals ¢t in the
cavity near Tyr-132, a location that can also be occupied by 5-
substituents of tightly binding uracil analogues [13]. The bind-
ing modes of aciclovir and HBPG are compared in Fig. 2.
One theoretical study of complexes of N2-phenylguanines
with TK predicted binding to TK in a manner distinct from
that found for the structurally related drug molecule ganciclo-
vir [11]. In another [14] the binding mode of the guanine of
HBPG was predicted to be similar, as now con¢rmed by this
X-ray study. As HBPG, by contrast with the drug molecules,
acts as an inhibitor rather than as substrate [8], the intriguing
question remains as to what is the structural basis for the
di¡erent properties. Given that the HBPG’s presentation is
similar to that of the weak substrate aciclovir, and its poten-
tial phosphate-binding function (the hydroxybutyl group) is
isosteric with aciclovir’s, it would appear that its inhibitory
properties arise from the much greater binding enthalpy that
the van der Waals interactions of the additional N2-phenyl
group give rise to. The high a⁄nity, arising, no doubt, from
these interactions, may restrict the £exibility of the complex to
allow phosphorylation of the ligand. It is also possible that
Vmax is su⁄ciently low, even compared to that of aciclovir,
that no phosphorylation of HBPG has been observed under
assay conditions [8].
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